Format

Send to

Choose Destination
Mod Rheumatol. 2016 Sep;26(5):662-6. doi: 10.3109/14397595.2015.1129692. Epub 2016 Feb 16.

Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.

Author information

1
a Unit of Translational Medicine, Department of Immunology and Rheumatology , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan .
2
b Department of Internal Medicine , Sasebo City General Hospital , Sasebo , Japan .
3
c Department of Rheumatology , The Japanese Red Cross Nagasaki Genbaku Hospital , Nagasaki , Japan .
4
d Department of Public health , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan .
5
e Department of Rheumatology , Japan Community Health Care Organization, Isahaya General Hospital , Isahaya , Japan .
6
f Department of Rheumatology , Sasebo Chuo Hospital , Sasebo , Japan , and.
7
g Department of Health Science , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.

Abstract

OBJECTIVE:

To evaluate the efficacy of switching the route from intravenous tocilizumab (TCZ) infusion (TCZ-IV) to subcutaneous TCZ injection (TCZ-SC) in a real-world setting through a comparison of the clinical response.

METHODS:

Fifty-eight rheumatoid arthritis (RA) patients, for whom TCZ-SC was initiated following TCZ-IV between June 2013 and August 2014, were consecutively enrolled. Disease activity score (DAS)28-ESR, simplified disease activity index (SDAI), and clinical disease activity index (CDAI) were examined at baseline and after switching from TCZ-IV to TCZ-SC for 3 months. We investigated whether body weight and body mass index (BMI) affected the efficacy of TCZ-SC.

RESULTS:

Most of the patients had achieved remission or low disease activity at baseline (77.6% examined by DAS28). Fifty-seven patients (98%) continued the TCZ-SC treatment, and the disease activity was well controlled after 3 months. ΔDAS28 tended to be worsened after switching to TCZ-SC in the high-body-weight groups (≥60 kg) as compared with the groups with body weight <60 kg, although no statistical significance was found. BMI did not affect the efficacy of TCZ-SC.

CONCLUSIONS:

Caution should be exercised in the high-body-weight subjects, but these data indicate that TCZ-SC maintains the favorable RA disease activity established using TCZ-IV.

KEYWORDS:

Rheumatoid arthritis; Subcutaneous injection; Tocilizumab

PMID:
26708444
DOI:
10.3109/14397595.2015.1129692
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center